Last reviewed · How we verify

NCT04066868

Evaluating the Use of Patient-Reported Outcome Measures for Improving the Inter-Rater Reliability of Common Terminology Criteria for Adverse Event Ratings

Completed NA Last updated 20 April 2025
What this trial tests

NA trial testing Patient-reported outcomes assessment in Cancer in 1,013 participants. Completed in 6 December 2024.

Timeline
10 February 2020
Primary endpoint
6 December 2024
6 December 2024

Quick facts

Lead sponsorMedical University Innsbruck
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment1,013
Start date10 February 2020
Primary completion6 December 2024
Estimated completion6 December 2024
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University Innsbruck

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open randomized trial investigates, if clinicians complete CTCAE ratings differently when receiving patients' patient-reported outcome (PRO) data prior to their CTCAE completion. The primary objective is to demonstrate superior inter-rater reliability of CTCAE ratings from physicians relying on EORTC PRO data as additional data source over traditional CTCAE ratings not including PRO information.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice.
    Gibbons C, Porter I, Gonçalves-Bradley DC, Stoilov S, et al · · 2021 · cited 146× · PMID 34637526 · DOI 10.1002/14651858.cd011589.pub2
  2. Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial.
    Wintner LM, Sztankay M, Abdel-Razeq H, Hamdan-Mansour R, et al · · 2026 · cited 3× · PMID 41570841 · DOI 10.1016/s1470-2045(25)00679-5
  3. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
    Wintner LM, Giesinger JM, Sztankay M, Bottomley A, et al · · 2020 · cited 2× · PMID 33050917 · DOI 10.1186/s13063-020-04745-w

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Medical University Innsbruck trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04066868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing